61 completed, 15 unknown, 8 not yet recruiting, 5 recruiting. 95 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 95 | Completed 61, Unknown 15, Not yet recruiting 8, Recruiting 5, Withdrawn 3, Terminated 2, Active not recruiting 1 |
Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial) Tamsulosin hydrochloride 0.2 mg, Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Shanghai East Hospital | 400 | 2026-12-01 | 2026-09-29 |
| Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation. Dutasteride (0.5mg), Placebo - Benign Prostatic Hyperplasia, Postoperative Hemorrhage | Phase 4 | Not yet recruiting | Mohamed Mahmoud Dogha | 44 | 2026-10-21 | 2026-11-02 |
| Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH. Zenflow Arm: Zenflow Spring System implant procedure, Medical Therapy Tamsulosin - Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS) | Phase 4 | Not yet recruiting | Zenflow, Inc. | 110 | 2026-09-01 | 2026-09-01 |
| Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Silodosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Tamsulosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 378 | 2026-06-08 | 2026-06-16 |
| Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, Tadalafil Placebo - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 320 | 2026-06-08 | 2026-06-17 |
| The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder Intravesical Botox injection - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Withdrawn | University Hospitals Cleveland Medical Center | 2026-06-01 | 2025-09-05 | |
| Tranexamic Acid for Bleeding Reduction During TURP Surgery Tranexamic Acid, Placebo (Normal Saline) - Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate | Phase 4 | Recruiting | Hamza Najout | 80 | 2026-03-30 | 2026-10-09 |
| Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial Silodosin, Tamsulosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Not yet recruiting | Ain Shams University | 140 | 2026-03-22 | 2026-03-16 |
| Comparison of Convective Water Vapor Ablation (Convective Water Vapor Energy, WAVE™) With the Rezum™ System Versus Holmium Laser Enucleation of the Prostate (HoLEP) Versus Bipolar Transurethral Resection of the Prostate (TUR-P) in Patients With Benign Prostatic Syndrome (BPS) - A Randomized Study Treatment BPH - BPH (Benign Prostatic Hyperplasia), HoLEP | Phase 4 | Not yet recruiting | Medical University of Graz | 198 | 2025-11-15 | 2025-11-19 |
| Standard Versus Double Alpha Blockers Treatment for Symptomatic Benign Prostatic Obstruction alpha blocker monotherapy Tamsulosin, alpha blockers Tamsulosin and Silodosin - BPH (Benign Prostatic Hyperplasia) | Phase 4 | Active not recruiting | Mansoura University | 140 | 2025-10-12 | 2026-11-05 |
| Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation Tranexamic Acid (IV), Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Kaiser Permanente | 56 | 2025-01-01 | 2024-11-29 |
| A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate Tamsulosin Hydrochloride Sustained-Release Capsules, Lingze Tablets - Benign Prostatic Hyperplasia, Nocturia Associated With Nocturnal Polyuria | Phase 4 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 136 | 2024-12-01 | 2026-01-22 |
| The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder. Pyridostigmine oral tablet, Placebo - Underactive Bladder, TURP(transurethral Resection of Prostate) | Phase 4 | Completed | Menoufia University | 66 | 2024-04-01 | 2025-03-26 |
| Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients With Prostate Volumes ≤ 40 ml: A Prospective Comparative Study Tamsulosin 0.4 mg, Tadalafil 5mg, Tamsulosin and Tadalafil - BPH With Other Lower Urinary Tract Symptoms | Phase 4 | Completed | Fayoum University Hospital | 95 | 2023-04-20 | 2025-02-05 |
| Role of Prophylactic Postoperative Antibiotics in HoLEP Nitrofurantoin, Cephalexin, Sulfamethoxazole Trimethoprim Combination - Benign Prostatic Hyperplasia, Urinary Tract Infections | Phase 4 | Withdrawn | Baylor Research Institute | 2023-03-01 | 2026-02-12 | |
| Prostate Medication, Metabolism and Gut Microbiota Prostate hyperplasia medication, LhRH-antagonist - Prostatic Hyperplasia, Prostate Cancer | Phase 4 | Recruiting | Turku University Hospital | 100 | 2022-12-01 | 2023-08-21 |
| The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH Silodosin, Tamsolusin - BPH (Benign Prostatic Hyperplasia) | Phase 4 | Completed | Shanghai Huilun Pharmaceutical Co., Ltd. | 110 | 2022-07-18 | 2025-08-21 |
| Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain Self-Administered Nitrous Oxide, Oxygen - Prostate Disease, Malignancy | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 143 | 2021-12-12 | 2024-01-30 |
Showing 20 of 95. Sign in to see all of them.
Lower Urinary Tract Symptoms (16) · Urinary Bladder, Overactive (9) · Prostatic Neoplasms (3) · Hypogonadism (2) · Iris Diseases (2) · Nocturia (2) · Pain (2) · Urinary Bladder Neoplasms (2) · Anemia (1) · Anxiety Disorders (1) · Cataract (1) · Choroid Diseases (1) · Coronary Artery Disease (1) · Ejaculatory Dysfunction (1)
Genital Diseases (95) · Genital Diseases, Male (95) · Male Urogenital Diseases (95) · Urogenital Diseases (95) · Prostatic Diseases (94) · Pathological Conditions, Signs and Symptoms (31) · Signs and Symptoms (28) · Urological Manifestations (26) · Female Urogenital Diseases (16) · Female Urogenital Diseases and Pregnancy Complications (16) · Urologic Diseases (15) · Urinary Bladder Diseases (12) · Lower Urinary Tract Symptoms (10) · Neoplasms by Site (5) · Urogenital Neoplasms (5)
Tamsulosin (28) · Dutasteride (12) · silodosin (11) · alfuzosin (8) · Tadalafil (6) · Finasteride (4) · Solifenacin Succinate (4) · Tranexamic Acid (3) · mirabegron (3) · saw palmetto extract (3) · Ciprofloxacin (2) · Doxazosin (2) · Photoelectron Spectroscopy (2) · Saline Solution (2) · 5-alpha Reductase Inhibitors (1)
GlaxoSmithKline (7) · Mansoura University (6) · Samsung Medical Center (5) · Astellas Pharma Inc (4) · Boehringer Ingelheim (4) · Sanofi (4) · Beni-Suef University (3) · JW Pharmaceutical (3) · Diskapi Yildirim Beyazit Education and Research Hospital (2) · Mohsen Pourazizi (2) · Pierre Fabre Medicament (2) · Royal Victoria Hospital, Canada (2) · Seoul National University Hospital (2) · Siami, Paul F., M.D. (2) · University of Florence (2)
United States (16) · Egypt (13) · South Korea (12) · France (8) · Italy (8) · Spain (6) · Canada (5) · Germany (5) · Netherlands (4) · Turkey (Türkiye) (4) · Czechia (3) · Japan (3) · Taiwan (3) · United Kingdom (3) · China (2)
Kyu-Sung Lee, Ph.D (4) · Ahmed M Elshal, MD (2) · Paul F Siami, MD (2) · Ahmed Elhefnawy (1) · Ahmed Elshal (1) · Albert Dahan, MD {hD (1) · Alexis Te, MD (1) · Alvin M Matsumoto, MD (1) · Andrey Z Vinarov, PhD (1) · Anil Kapoor, MD, FRCSC (1)
PMID 16465187, PMID 19394149, PMID 19732305, PMID 21251673, PMID 21575967, PMID 21738005, PMID 22010203, PMID 23452344, PMID 25261801, PMID 25613154, PMID 26544316, PMID 27324263, PMID 29044968, PMID 29394114, PMID 31148056, PMID 31961963, PMID 32558340, PMID 33245533, PMID 34314241, PMID 34725072, PMID 36222618, PMID 37160401, PMID 40977319, PMID 42406401
2014 (1), 2015 (1), K12DK111028 (1)